Polianta Ltd Invests $1.20 Million in United Therapeutics Co. (NASDAQ:UTHR)

Polianta Ltd purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,900 shares of the biotechnology company's stock, valued at approximately $1,202,000. United Therapeutics makes up approximately 0.6% of Polianta Ltd's portfolio, making the stock its 28th largest holding.

A number of other hedge funds have also recently made changes to their positions in UTHR. Dunhill Financial LLC grew its holdings in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. State of Wyoming acquired a new stake in shares of United Therapeutics in the 4th quarter worth $62,000. Millstone Evans Group LLC purchased a new position in United Therapeutics during the 4th quarter worth $67,000. Curat Global LLC purchased a new position in United Therapeutics during the 1st quarter worth $63,000. Finally, Natixis acquired a new position in United Therapeutics during the 4th quarter valued at about $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $2.79 during trading on Friday, hitting $283.35. 564,424 shares of the company's stock were exchanged, compared to its average volume of 452,608. United Therapeutics Co. has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market capitalization of $12.78 billion, a price-to-earnings ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57. The business has a 50-day simple moving average of $300.43 and a 200-day simple moving average of $331.51.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the business posted $6.17 EPS. The company's revenue was up 17.2% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. This trade represents a 22.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer now owns 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 68,500 shares of company stock worth $20,828,390. 10.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.